Vyant Bio (VYNT) 10-Q 20 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 14, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	CANCER GENETICS, INC
Trading Symbol	CGIX
Entity Central Index Key	0001349929
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding (in shares)		57,816,037

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash and cash equivalents	$ 697	$ 161
Accounts receivable, net of allowance for doubtful accounts of $3,462	7,292	7,038
Other current assets	2,344	2,148
Total current assets	10,333	9,347
FIXED ASSETS, net of accumulated depreciation	3,821	4,056
OTHER ASSETS
Operating lease right-of-use assets	2,422
Restricted cash	350	350
Patents and other intangible assets, net of accumulated amortization	3,917	4,004
Investment in joint venture	92	92
Goodwill	17,257	17,257
Other	300	300
Total other assets	24,338	22,003
Total Assets	38,492	35,406
CURRENT LIABILITIES
Accounts payable and accrued expenses	11,561	13,067
Operating lease liabilities	1,086
Obligations under finance leases, current portion	321
Obligations under finance leases, current portion		330
Deferred revenue	2,604	2,173
Line of credit	2,414	2,621
Term note	6,000	6,000
Convertible note, net	2,778	2,481
Advance from NovellusDx, Ltd., net	1,500	535
Other derivatives	55	86
Total current liabilities	28,319	27,293
Obligations under finance leases	294
Obligations under finance leases		379
Operating lease liabilities, non-current	1,542
Deferred rent payable and other	0	305
Warrant liability	255	248
Deferred revenue, long-term	403	379
Total Liabilities	30,813	28,604
STOCKHOLDERS’ EQUITY
Preferred stock, authorized 9,764 shares, $0.0001 par value, none issued	0	0
Common stock, authorized 100,000 shares, $0.0001 par value, 56,276 and 27,726 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively	6	3
Additional paid-in capital	170,022	164,455
Accumulated other comprehensive income (loss)	(16)	60
Accumulated (deficit)	(162,333)	(157,716)
Total Stockholders’ Equity	7,679	6,802
Total Liabilities and Stockholders’ Equity	$ 38,492	$ 35,406

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, shares authorized (in shares)	9,764,000	9,764,000
Preferred stock, par value (usd per share)	$ 0.0001	$ 0.0001
Preferred stock, shares issued (in shares)	0	0
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, par value (usd per share)	$ 0.0001	$ 0.0001
Common stock, shares issued (in shares)	56,276,000	27,726,000
Common stock, shares outstanding (in shares)	56,276,000	27,726,000
Allowance for doubtful accounts	$ 3,462	$ 3,462

Consolidated Statements of Oper

Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Revenue	$ 6,839	$ 7,667
Cost of revenues	4,637	5,082
Gross profit	2,202	2,585
Operating expenses:
Research and development	454	681
General and administrative	3,309	5,260
Sales and marketing	1,108	1,591
Merger costs	249	0
Total operating expenses	5,120	7,532
Loss from operations	(2,918)	(4,947)
Other income (expense):
Interest expense	(1,725)	(239)
Interest income	2	21
Change in fair value of acquisition note payable	0	17
Change in fair value of other derivatives	31	0
Change in fair value of warrant liability	(7)	692
Total other income (expense)	(1,699)	491
Net (loss)	$ (4,617)	$ (4,456)
Basic and diluted net (loss) per share (usd per share)	$ (0.09)	$ (0.16)
Basic and diluted weighted-average shares outstanding (in shares)	48,933	27,049
Foreign currency translation (loss)	$ (76)	$ (20)
Comprehensive (loss)	$ (4,693)	$ (4,476)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Employees	EmployeesCommon Stock	EmployeesAdditional Paid-in Capital	2019 Offerings	2019 OfferingsCommon Stock	2019 OfferingsAdditional Paid-in Capital
Beginning balance (in shares) at Dec. 31, 2017		27,754,000
Beginning balance at Dec. 31, 2017	$ 26,765	$ 3	$ 161,527	$ 69	$ (134,834)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock based compensation—employees (in shares)							(24,000)
Stock based compensation—employees						$ 274		$ 274
Unrealized loss on foreign currency translation	(20)			(20)
Net (loss)	(4,456)				(4,456)
Ending balance (in shares) at Mar. 31, 2018		27,730,000
Ending balance at Mar. 31, 2018	20,054	$ 3	161,801	49	(141,799)
Beginning balance (in shares) at Dec. 31, 2018		27,726,000
Beginning balance at Dec. 31, 2018	6,802	$ 3	164,455	60	(157,716)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock based compensation—employees						$ 158		$ 158
Issuance of common stock - 2019 Offerings, net (in shares)										28,550,000
Issuance of common stock - 2019 Offerings, net									$ 5,412	$ 3	$ 5,409
Unrealized loss on foreign currency translation	(76)			(76)
Net (loss)	(4,617)				(4,617)
Ending balance (in shares) at Mar. 31, 2019		56,276,000
Ending balance at Mar. 31, 2019	$ 7,679	$ 6	$ 170,022	$ (16)	$ (162,333)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss)	$ (4,617)	$ (4,456)
Adjustments to reconcile net (loss) to net cash (used in) operating activities:
Depreciation	270	429
Amortization	86	135
Provision for bad debts	0	464
Stock-based compensation	158	274
Change in fair value of warrant liability, acquisition note payable and other derivatives	(24)	(709)
Amortization of discount of debt and debt issuance costs	1,060	0
Interest added to Convertible Note	202	0
Loss in equity-method investment	0	2
Changes in:
Accounts receivable	(254)	(160)
Other current assets	(274)	(143)
Operating lease right-of-use assets	221
Other non-current assets	0	(5)
Accounts payable, accrued expenses and deferred revenue	(1,051)	(279)
Operating lease liabilities	(242)
Deferred rent payable and other	0	(24)
Net cash (used in) operating activities	(4,465)	(4,472)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of fixed assets	(32)	(221)
Patent costs	0	(32)
Net cash (used in) investing activities	(32)	(253)
CASH FLOWS FROM FINANCING ACTIVITIES
Principal payments on finance lease obligations	(94)
Principal payments on finance lease obligations		(86)
Proceeds from offerings of common stock, net of certain offering costs	5,412	0
Proceeds from borrowings on Silicon Valley Bank line of credit	4,915	0
Repayment of borrowings on Silicon Valley Bank line of credit	(5,122)	(627)
Net cash provided by (used in) financing activities	5,111	(713)
Effect of foreign exchange rates on cash and cash equivalents and restricted cash	(78)	(32)
Net increase (decrease) in cash and cash equivalents and restricted cash	536	(5,470)
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH
Beginning	511	9,891
Ending	1,047	4,421
SUPPLEMENTAL CASH FLOW DISCLOSURE
Cash paid for interest	$ 304	245
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES
Fixed assets acquired through capital lease arrangements		$ 150

Organization, Description of Bu

Organization, Description of Business, Basis of Presentation, 2019 Offerings, Forbearance Agreements, Standstill Agreements, Recently Adopted Accounting Standard, and Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Description of Business, Basis of Presentation, 2019 Offerings, Forbearance Agreements, Standstill Agreements, Recently Adopted Accounting Standard, and Recent Accounting Pronouncements	Organization, Description of Business, Basis of Presentation, 2019 Offerings, Forbearance Agreements, Standstill Agreements, Recently Adopted Accounting Standard, and Recent Accounting Pronouncements We are an emerging leader in enabling precision medicine in oncology by providing multi-disciplinary diagnostic and data solutions, facilitating individualized therapies through our diagnostic tests, services and molecular markers. We develop, commercialize and provide molecular- and biomarker-based tests and services, including proprietary preclinical oncology and immuno-oncology services, that enable biotech and pharmaceutical companies engaged in oncology and immuno-oncology trials to better select candidate populations and reduce adverse drug reactions by providing information regarding genomic and molecular factors influencing subject responses to therapeutics. Through our clinical services, we enable physicians to personalize the clinical management of each individual patient by providing genomic information to better diagnose, monitor and inform cancer treatment. We have a comprehensive, disease-focused oncology testing portfolio, and extensive set of anti-tumor referenced data based on predictive xenograft and syngeneic tumor models. Our tests and techniques target a wide range of indications, covering all ten of the top cancers in prevalence in the United States, with additional unique capabilities offered by our FDA-cleared Tissue of Origin® test for identifying difficult to diagnose tumor types or poorly differentiated metastatic disease. Following the acquisition of vivoPharm, Pty Ltd. (“vivoPharm”) we provide contract research services, focused primarily on unique specialized studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. We were incorporated in the State of Delaware on April 8, 1999 and currently have offices and state-of-the-art laboratories located in New Jersey, North Carolina, Pennsylvania, and Australia. Our laboratories comply with the highest regulatory standards as appropriate for the services they deliver including CLIA, CAP, and NY State. Our services are built on a foundation of world-class scientific knowledge and intellectual property in solid and blood-borne cancers, as well as strong academic relationships with major cancer centers such as Memorial Sloan-Kettering, Mayo Clinic, and the National Cancer Institute. We offer preclinical services such as predictive tumor models, human orthotopic xenografts and syngeneic immuno-oncology relevant tumor models in our Hershey PA facility, and a leader in the field of immuno-oncology preclinical services in the United States. This service is supplemented with GLP toxicology and extended bioanalytical services in our Australian based facility in Bundoora VIC. Basis of Presentation The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions for interim reporting as prescribed by the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2018 , filed with the Securities and Exchange Commission on April 16, 2019. The consolidated balance sheet as of December 31, 2018 , included herein was derived from the audited financial statements as of that date, but does not include all disclosures including notes required by GAAP. Interim financial results are not necessarily indicative of the results that may be expected for any future interim period or for the year ending December 31, 2019 . Derivative Liabilities The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company’s financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as a liability and the change in fair value is recorded in other income (expense) in the consolidated results of operations. In circumstances where there are multiple embedded instruments that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date. When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption and are classified in interest expense in the consolidated results of operations. 2019 Offerings On January 9, 2019, we entered into an underwriting agreement with H.C. Wainwright & Co., LLC (“H.C. Wainwright”), relating to an underwritten public offering of 13,333,334 shares of our common stock for $0.225 per share. We received proceeds from the offering of approximately $2,437,000 , net of expenses and discounts of approximately $563,000 . We also issued warrants to purchase 933,334 shares of common stock to H.C. Wainwright in connection with this offering. The warrants are exercisable for five years from the date of issuance at a per share price of $0.2475 . On January 26, 2019, we issued 15,217,392 shares of common stock at a public offering price of $0.23 per share. We received proceeds from the offering of approximately $2,975,000 , net of expenses and discounts of approximately $525,000 . We also issued warrants to purchase 1,065,217 shares of common stock to the underwriter, H.C. Wainwright, in connection with this offering. The warrants are exercisable for five years from the date of issuance at a per share price of $0.253 . The January 9, 2019 and January 26, 2019 offerings will be referred to collectively as the “2019 Offerings.” As disclosed in Note 13, certain of our directors and executive officers purchased shares in the 2019 Offerings at the public offering price. Forbearance Agreements On January 16, 2019, we entered into forbearance agreements with both Partners for Growth IV, L.P. (“PFG”) and Silicon Valley Bank (“SVB”) that among other things, (i) required us to comply with certain milestones in connection with a potential strategic transaction satisfactory to PFG and SVB with an anticipated closing date of on or before April 15, 2019 (the “Milestones”), and (ii) provided for PFG and SVB’s forbearance of their respective rights and remedies resulting from existing and stated potential events of default under the $6.0 million term note (“PFG Term Note”) and SVB asset-based line of credit (“ABL”) until the earlier of (a) the occurrence of an additional event of default or (b) February 15, 2019; provided such date was to automatically extend to (1) February 28, 2019 and then to (2) April 15, 2019 so long as we were in compliance with the Milestones required as of such dates. In addition, the ABL interest rate was increased to 2.25% over the Wall Street Journal prime rate, and the maturity date was extended until April 15, 2019. While the expired forbearance agreements with PFG and SVB acknowledged that we were and anticipated that we would be in violation of certain financial and other covenants of the ABL and the PFG Term Note as of December 31, 2018, January 31, 2019, February 28, 2019 and March 31, 2019, the ABL is currently past its maturity date. We are in discussions with SVB and PFG about possible extensions of the forbearance agreements and of the maturity of the ABL as part of the overall strategic process. Standstill Agreements On February 15, 2019, we entered into a standstill agreement with Iliad Research and Trading, L.P. (“Iliad”), related to the $2,625,000 convertible promissory note dated July 17, 2018 (“Convertible Note”) described further in Note 6. The standstill agreement, among other things, provided that Iliad will not seek to redeem any portion of the Convertible Note until April 15, 2019 (the “Standstill”) and increased the outstanding balance of the Convertible Note by approximately $202,000 , representing a fee to Iliad for such Standstill. In May 2019, we entered into a second standstill agreement with Iliad (“Second Standstill”). The Second Standstill provides that Iliad will not seek to redeem any portion of the Convertible Note until May 31, 2019. In consideration for the Second Standstill, we agreed to adjust the conversion price on the first $1,250,000 of our debt to Iliad from $0.80 to $0.2273 . The Standstill and Second Standstill are referred to collectively as the Standstill Agreements. In May 2019, Iliad converted $350,000 of the Convertible Note balance into 1,539,815 shares of our common stock at a conversion price of $0.2273 per share. Advance from NovellusDx, Ltd. On September 18, 2018, we entered into an agreement and plan of merger (“Merger Agreement”) with NovellusDx, Ltd. (“NDX”). In connection with signing the Merger Agreement, NDX loaned us $1,500,000 (“Advance from NDX”). Interest accrued on the outstanding balance at 10.75% per annum until we terminated the Merger Agreement on December 15, 2018. As a result of the termination, the Advance from NDX, plus interest thereon, became due and payable on March 15, 2019 . The Company and NDX are currently negotiating a possible resolution or settlement of the Advance from NDX. Recently Adopted Accounting Standards In February 2016, the Financial Accounting Standards Board (“FASB”) issued guidance codified in Accounting Standards Codification (“ASC”) 842, Leases , which supersedes the guidance in former ASC 840, Leases , to increase transparency and comparability among organizations by requiring recognition of right-of-use assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements (with the exception of short-term leases). In July 2018, the FASB issued Accounting Standards Update (“ASU”) 2018-11 to the existing transition guidance that allows entities to recognize a cumulative-effect adjustment to the opening balance of accumulated deficit in the period of adoption. Effective January 1, 2019, we adopted ASC 842 using this new transition guidance. The comparative information has not been restated and continues to be reported under the accounting standard in effect for those periods. We have elected to use the package of practical expedients, which allows us to not (1) reassess whether any expired or existing contracts are considered or contain leases; (2) reassess the lease classification for any expired or existing leases; and (3) reassess the initial direct costs for any existing leases. We did not elect the hindsight practical expedient, which permits entities to use hindsight in determining the lease term and assessing impairment. The most significant impact of adopting ASC 842 is related to the recognition of right-of-use assets and lease liabilities for operating leases. Our accounting for finance leases remains substantially unchanged. The adoption of ASC 842 had no impact on our consolidated statements of operations or total cash flows from operations. The cumulative effect of the changes made to our consolidated January 1, 2019 balance sheet for the adoption of ASC 842 were as follows (in thousands): As of December 31, 2018 Adjustment for Adoption of ASC 842 As of January 1, 2019 ASSETS Operating lease right-of-use assets $ — $ 2,643 $ 2,643 Other current assets 2,148 (78 ) 2,070 $ 2,148 $ 2,565 $ 4,713 LIABILITIES Operating lease liabilities $ — $ 1,080 $ 1,080 Deferred rent payable and other 305 (305 ) — Operating lease liabilities, non-current — 1,790 1,790 $ 305 $ 2,565 $ 2,870 Recent Accounting Pronouncements In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract , which clarifies the accounting for implementation costs in cloud computing arrangements. The update will become effective for interim and annual periods beginning after December 15, 2019 and may be adopted either retrospectively or prospectively. Early adoption is permitted. We plan to adopt this standard prospectively. We are currently evaluating the impact that adoption of this ASU will have on our consolidated financial statements and whether or not to early adopt. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): “ Simplifying the Accounting for Goodwill Impairment ,” which removes the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective for annual periods beginning after December 15, 2019, and interim periods within those annual periods. Early adoption is permitted and applied prospectively. We do not expect ASU 2017-04 to have a material impact on our consolidated financial statements.

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Going Concern At March 31, 2019 , our cash position and history of losses required management to assess our ability to continue operating as a going concern, according to FASB ASC 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The Company does not have sufficient cash at March 31, 2019 to fund normal operations beyond the next three months from the date of this report. In addition, while the expired forbearance agreements with PFG and SVB acknowledged that we were and anticipated that we would be in violation of certain financial and other covenants of the ABL and the PFG Term Note as of December 31, 2018, January 31, 2019, February 28, 2019 and March 31, 2019, the ABL is currently past its maturity date. We are in discussions with SVB and PFG about possible extensions of the forbearance agreements and of the maturity of the ABL as part of the overall strategic process. The Company’s ability to continue as a going concern is dependent on the Company’s ability to extend the forbearance agreements and the term of the ABL, raise additional equity or debt capital or spin-off non-core assets to raise additional cash. These factors raise substantial doubt about the Company's ability to continue as a going concern. Net cash used in operating activities was $4.5 million and $4.5 million for the three months ended March 31, 2019 and 2018 , respectively, and the Company had unrestricted cash and cash equivalents of $0.7 million at March 31, 2019 , an increase from $0.2 million at December 31, 2018 . The Company has negative working capital at March 31, 2019 of $18.0 million . The Company currently requires a significant amount of additional capital to fund operations and pay its accounts payable, and its ability to continue as a going concern is dependent upon its ability to raise such additional capital and achieve profitability. Raymond James & Associates, Inc. continues to assist us with evaluating strategic options. Such options could include raising more capital, the sale of the Company or another type of strategic partnership. We have reduced our cost of sales and operating expenses by migrating our California laboratory services to New Jersey and North Carolina during the third quarter of 2018, and we are continuing to pursue strategies to reduce our operating costs. We can provide no assurances that our current actions will be successful or that additional sources of financing with be available to us on favorable terms, if at all. If the Company is not able to raise such additional capital on a timely basis or on favorable terms, the Company may need to scale back or, in extreme cases, discontinue its operations or liquidate its assets. The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

Revenue and Accounts Receivable

Revenue and Accounts Receivable	3 Months Ended
	Mar. 31, 2019
Revenue from Contract with Customer [Abstract]
Revenue and Accounts Receivable	Revenue and Accounts Receivable Revenue by service type for the three months ended March 31, 2019 and 2018 is comprised of the following (in thousands): Three Months Ended March 31, 2019 2018 Biopharma Services $ 3,964 $ 3,658 Clinical Services 1,353 2,342 Discovery Services 1,522 1,667 $ 6,839 $ 7,667 Discovery Services revenue for the three months ended March 31, 2018 includes approximately $239,000 of revenue from our India subsidiary that was sold in April 2018. Accounts receivable by service type at March 31, 2019 and December 31, 2018 consists of the following (in thousands): March 31, December 31, Biopharma Services $ 3,967 $ 3,692 Clinical Services 5,906 6,031 Discovery Services 881 777 Allowance for doubtful accounts (3,462 ) (3,462 ) $ 7,292 $ 7,038 Revenue for Biopharma Services are customized solutions for providing information regarding genomic and molecular factors influencing subject responses to therapeutics. Biopharma Services are billed to pharmaceutical and biotechnology companies. Clinical Services are tests performed to provide information on diagnosis of cancers to guide patient management. Clinical Services tests can be billed to Medicare, another third party insurer or the referring community hospital or other healthcare facility, or directly to patients. Discovery Services are services that provide the tools and testing methods for companies and researchers seeking to identify new DNA-based biomarkers for disease. The breakdown of our Clinical Services revenue (as a percent of total revenue) is as follows: Three Months Ended March 31, 2019 2018 Medicare 5% 9% Other third party payors 15% 21% 20% 30% We have historically derived a significant portion of our revenue from a limited number of test ordering sites. Test ordering sites account for all of our Clinical Services revenue. Our test ordering sites are largely hospitals, cancer centers, reference laboratories, physician offices and biopharmaceutical companies. Oncologists and pathologists at these sites order the tests on behalf of the needs of their oncology patients or as part of a clinical trial sponsored by a biopharmaceutical company in which the patient is being enrolled. We generally do not have formal, long-term written agreements with such test ordering sites, and, as a result, we may lose a significant test ordering site at any time, except with biopharmaceutical companies. Remaining Performance Obligations : Services offered under the Biopharma and Discovery Services frequently take time to complete under their respective contacts. These times vary depending on specific contract arrangements including the length of the study and how samples are delivered to us for processing. In the case of Clinical Services and Discovery Services, the duration of performance obligations is less than one year . As of March 31, 2019 , the Company had approximately $36.8 million in remaining performance obligations in the Biopharma Services area. We expect to recognize the remaining performance obligations over the next two years .

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share For purposes of this calculation, stock warrants, outstanding stock options, convertible debt and unvested restricted shares are considered common stock equivalents using the treasury stock method, and are the only such equivalents outstanding. For all periods presented, all common stock equivalents outstanding were anti-dilutive. The following table summarizes equivalent units outstanding that were excluded from the earnings per share calculation because their effects were anti-dilutive (in thousands): Three Months Ended March 31, 2019 2018 Common stock purchase warrants 12,053 10,055 Stock options 2,290 2,534 Convertible note 3,767 — Advance from NovellusDx, Ltd. 2,690 — Restricted shares of common stock 28 683 20,828 13,272

Leasing Arrangments

Leasing Arrangments	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Leasing Arrangements	Leasing Arrangements Operating Leases We lease our laboratory, research facility and administrative office space under various operating leases. We also lease office and scientific equipment under various finance leases. We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, operating lease liabilities, and operating lease liabilities, non-current on our consolidated balance sheets. Finance leases are included in fixed assets, net of accumulated depreciation and obligations under finance leases. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Our incremental borrowing rate was determined by adjusting our secured borrowing interest rate for the longer-term nature of our leases. Our variable lease payments primarily consist of maintenance and other operating expenses from our real estate leases. Variable lease payments are excluded from the ROU assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives incurred. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. We have lease agreements with lease and non-lease components. We have elected to account for these lease and non-lease components as a single lease component. We are also electing not to apply the recognition requirements to short-term leases of twelve months or less and instead will recognize lease payments as expense on a straight-line basis over the lease term. The components of lease expense were as follows for the three months ended March 31, 2019 (in thousands): Operating lease cost $ 276 Short-term lease cost 24 Variable lease cost 62 Total lease expense $ 362 Other supplemental information related to leases was as follows for the three months ended March 31, 2019 : Weighted average remaining lease term (in years) Operating leases 3.18 Weighted average discount rate Operating leases 7.87 % We did not enter into any new leases that met scope during the three months ended March 31, 2019 . At March 31, 2019 , future estimated minimum lease payments under non-cancelable operating leases were as follows (in thousands): 2019 (remaining 9 months) $ 860 2020 966 2021 598 2022 563 2023 94 Total minimum lease payments 3,081 Less amount representing interest 453 Total $ 2,628
Leasing Arrangements	Leasing Arrangements Operating Leases We lease our laboratory, research facility and administrative office space under various operating leases. We also lease office and scientific equipment under various finance leases. We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, operating lease liabilities, and operating lease liabilities, non-current on our consolidated balance sheets. Finance leases are included in fixed assets, net of accumulated depreciation and obligations under finance leases. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Our incremental borrowing rate was determined by adjusting our secured borrowing interest rate for the longer-term nature of our leases. Our variable lease payments primarily consist of maintenance and other operating expenses from our real estate leases. Variable lease payments are excluded from the ROU assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives incurred. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. We have lease agreements with lease and non-lease components. We have elected to account for these lease and non-lease components as a single lease component. We are also electing not to apply the recognition requirements to short-term leases of twelve months or less and instead will recognize lease payments as expense on a straight-line basis over the lease term. The components of lease expense were as follows for the three months ended March 31, 2019 (in thousands): Operating lease cost $ 276 Short-term lease cost 24 Variable lease cost 62 Total lease expense $ 362 Other supplemental information related to leases was as follows for the three months ended March 31, 2019 : Weighted average remaining lease term (in years) Operating leases 3.18 Weighted average discount rate Operating leases 7.87 % We did not enter into any new leases that met scope during the three months ended March 31, 2019 . At March 31, 2019 , future estimated minimum lease payments under non-cancelable operating leases were as follows (in thousands): 2019 (remaining 9 months) $ 860 2020 966 2021 598 2022 563 2023 94 Total minimum lease payments 3,081 Less amount representing interest 453 Total $ 2,628

Financing

Financing	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Financing	Financing Term Note and Line of Credit On March 22, 2017, we entered into a two year asset-based revolving line of credit agreement (“ABL”) with SVB. The SVB credit facility provided for an ABL for an amount not to exceed the lesser of (a) $6.0 million or (b) 80% of eligible accounts receivable plus the lesser of 50% of the net collectible value of third party accounts receivable or three ( 3 ) times the average monthly collection amount of third party accounts receivable over the previous quarter. The ABL required monthly interest payments at the Wall Street Journal prime rate plus 1.50% and was scheduled to mature on March 22, 2019. We also pay a fee of 0.25% per year on the average unused portion of the ABL. In August 2018, the maximum borrowings were reduced from $6.0 million to $3.0 million . In January 2019, the interest rate was adjusted to the Wall Street Journal prime rate plus 2.25% ( 7.75% at March 31, 2019 ) and the maturity date was extended through April 15, 2019, subject to the Company satisfying certain milestones of the forbearance agreement discussed in Note 1. At March 31, 2019 , we have borrowings of approximately $2.4 million on the ABL. We concurrently entered into the PFG Term Note, which is a three year $6.0 million term loan agreement. The PFG Term Note is an interest only loan with the full principal and any outstanding interest due at maturity on March 22, 2020. Interest is payable monthly at a rate of 11.5% per annum. We may prepay the PFG Term Note in whole or part at any time without penalty. At March 31, 2019 , the principal amount of the PFG Term Note was $6,000,000 . Both loan agreements require us to comply with certain financial covenants, including minimum adjusted EBITDA, revenue and liquidity covenants, and restrict us from, among other things, paying cash dividends, incurring debt and entering into certain transactions without the prior consent of the lenders. Repayment of amounts borrowed under the loan agreements may be accelerated if an event of default occurs, which includes, among other things, a violation of such financial covenants and negative covenants. While the expired forbearance agreements with PFG and SVB acknowledged that we were and anticipated that we would be in violation of certain financial and other covenants of the ABL and the PFG Term Note as of December 31, 2018, January 31, 2019, February 28, 2019 and March 31, 2019, the ABL is currently past its maturity date. We are in discussions with SVB and PFG about possible extensions of the forbearance agreements and of the maturity of the ABL as part of the overall strategic process. During the three months ended March 31, 2019 , the Company incurred approximately $167,000 of lender fees associated with the forbearance agreements that were expensed due to prior and expected future violations of the covenants. Our obligations to SVB under the ABL facility are secured by a first priority security interest on substantially all of our assets, and our obligations under the PFG Term Note are secured by a second priority security interest subordinated to the SVB lien. Convertible Note On July 17, 2018, the Company entered into the Convertible Note, pursuant to which the Company issued a convertible promissory note to an institutional accredited investor in the initial principal amount of $2,625,000 . The Company received consideration of $2,500,000 , reflecting an original issue discount of $100,000 , a beneficial conversion feature discount of approximately $328,000 and expenses payable by the Company of $25,000 . The Convertible Note has an 18 month term and carries interest at 10% per annum. The note is convertible into shares of the Company’s common stock at a conversion price of $0.80 per share (“Conversion Price”) upon five trading days’ notice, subject to certain adjustments (standard dilution) and ownership limitations specified in the Convertible Note. In May 2019, the conversion price was reduced to $0.2273 for $1,250,000 of the balance of the Convertible Note; the remainder is still convertible at $0.80 . Prior to the Standstill Agreements, the investor could redeem any portion of the Convertible Note upon five trading days’ notice, beginning January 17, 2019, subject to a maximum monthly redemption amount of $650,000 , with the Company having the option to pay such redemptions in cash, the Company’s common stock at the Conversion Price, or by a combination thereof, subject to certain conditions, including that the stock price is $1.00 per share or higher. After taking into consideration the Standstill Agreements, Iliad cannot request a monthly redemption until June 1, 2019. The Company may prepay the outstanding balance of the Convertible Note, in part or in full, at a 10% premium to par value if prior to the one year anniversary of the date of issuance and at par if prepaid thereafter. At maturity, the Company may pay the outstanding balance in cash, the Company’s common stock at the Conversion Price, or by a combination thereof, subject to certain conditions. The note provides that in the event of default, the lender may, at its option, elect to increase the outstanding balance applying the default effect (defined as outstanding balance at date of default multiplied by 15% plus outstanding amount) by providing written notice to the Company. In addition, the interest rate increases to 22% upon default. The default effect and default interest rate provisions qualify as embedded derivatives with an estimated fair value of $55,000 at March 31, 2019 . The Convertible Note is the general unsecured obligation of the Company and is subordinated in right of payment to the ABL and PFG Term Note. The following is a summary of the Convertible Note balance at March 31, 2019 (in thousands): Convertible Note, net of discounts of $46 $ 2,781 Less unamortized debt issuance costs 3 Convertible Note, net $ 2,778 In May 2019, Iliad converted $350,000 of the Convertible Note balance into 1,539,815 shares of our common stock at $0.2273 per share. Advance from NDX On September 18, 2018, we entered into the Merger Agreement with NDX. In connection with signing the Merger Agreement, NDX loaned us $1,500,000 . Interest accrued on the outstanding balance at 10.75% per annum until we terminated the Merger Agreement on December 15, 2018. As a result of the termination, the Advance from NDX, plus interest thereon, became due and payable on March 15, 2019 . The termination was a specified event of default, so on December 15, 2018, the interest rate was increased to 21% . The default also gives NDX the right to convert all, but not less than all, of the outstanding balance into shares of the Company’s common stock at a conversion price of $0.606 per share. At March 31, 2019 , the principal balance of the Advance from NDX was $1,500,000 . The Advance from NDX is the general unsecured obligation of the Company and is subordinated in right of payment to the ABL and PFG Term Note, provided that NDX has asserted that its obligation to standstill under its subordination agreements will not be applicable at a time when the Company attains certain levels of unrestricted cash, as a result of the Company having improperly terminated the Merger Agreement. The Company does not believe it improperly terminated the Merger Agreement. The Company and NDX are currently negotiating a possible resolution or settlement of the Advance from NDX.

Capital Stock

Capital Stock	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Capital Stock	Capital Stock 2019 Offerings On January 9, 2019, we entered into an underwriting agreement with H.C. Wainwright & Co., LLC (“H.C. Wainwright”), relating to an underwritten public offering of 13,333,334 shares of our common stock for $0.225 per share. We received proceeds from the offering of approximately $2,437,000 , net of expenses and discounts of approximately $563,000 . On January 26, 2019, we issued 15,217,392 shares of common stock at a public offering price of $0.23 per share. We received proceeds from the offering of approximately $2,975,000 , net of expenses and discounts of approximately $525,000 . In May 2019, Iliad converted $350,000 of the Convertible Note into an aggregate of 1,539,815 shares of our common stock at a conversion price of $0.2273 per share.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation We have two equity incentive plans: the 2008 Stock Option Plan (the “2008 Plan”) and the 2011 Equity Incentive Plan (the “2011 Plan”, and together with the 2008 Plan, the “Stock Option Plans”). The Stock Option Plans are meant to provide additional incentive to officers, employees and consultants to remain in our employment. Options granted are generally exercisable for up to 10 years . Effective April 9, 2018, the Company cannot issue additional options from the 2008 Plan. At March 31, 2019 , 730,051 shares remain available for future awards under the 2011 Plan. A summary of employee and non-employee stock option activity for the three months ended March 31, 2019 is as follows: Options Outstanding Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Number of Shares (in thousands) Weighted- Average Exercise Price Outstanding January 1, 2019 3,004 $ 5.77 5.70 $ — Granted 95 0.44 Cancelled or expired (809 ) 8.00 Outstanding March 31, 2019 2,290 $ 4.76 7.13 $ — Exercisable March 31, 2019 1,189 $ 7.94 5.42 $ — Aggregate intrinsic value represents the difference between the fair value of our common stock and the exercise price of outstanding, in-the-money options. As of March 31, 2019 , total unrecognized compensation cost related to non-vested stock options granted to employees was $780,553 which we expect to recognize over the next 3.20 years. The fair value of options granted to employees is estimated on the grant date using the Black-Scholes option valuation model. This valuation model requires us to make assumptions and judgments about the variables used in the calculation, including the expected term (the period of time that the options granted are expected to be outstanding), the volatility of our common stock, a risk-free interest rate, and expected dividends. Forfeitures will be recorded when they occur. No compensation cost is recorded for options that do not vest. We use the simplified calculation of expected life described in the SEC’s Staff Accounting Bulletin No. 107, Share-Based Payment , and volatility is based on the historical volatility of our common stock. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. We use an expected dividend yield of zero , as we do not anticipate paying any dividends in the foreseeable future. The following table presents the weighted-average assumptions used to estimate the fair value of options granted to employees during the periods presented: Three Months Ended March 31, 2019 Volatility 90.15 % Risk free interest rate 2.54 % Dividend yield 0.00 % Term (years) 6.32 Weighted-average fair value of options granted during the period $ 0.34 Restricted stock awards have been granted to employees, directors and consultants as compensation for services. At March 31, 2019 , there was $34,285 of unrecognized compensation cost related to non-vested restricted stock granted to employees and directors; we expect to recognize the cost over 0.44 years. The following table summarizes the activities for our non-vested restricted stock awards for the three months ended March 31, 2019 : Non-vested Restricted Stock Awards Number of Weighted-Average Grant Date Fair Value Non-vested at January 1, 2019 29 $ 3.43 Cancelled (1 ) 6.30 Non-vested at March 31, 2019 28 $ 3.33 The following table presents the effects of stock-based compensation related to stock option and restricted stock awards to employees and non-employees on our Consolidated Statements of Operations and Other Comprehensive Loss during the periods presented (in thousands): Three Months Ended March 31, 2019 2018 Cost of revenues $ 28 $ 91 Research and development 8 15 General and administrative 116 158 Sales and marketing 6 10 Total stock-based compensation $ 158 $ 274

Warrants

Warrants	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Warrants	Warrants On January 14, 2019, we issued 933,334 warrants to purchase common stock at $0.2475 per share. The warrants are immediately exercisable and expire on January 9, 2024. On January 31, 2019 we issued 1,065,217 warrants to purchase common stock at $0.253 per share. These warrants are immediately exercisable and expire on January 26, 2024. All of these warrants were issued in conjunction with the 2019 Offerings. The following table summarizes the warrant activity for the three months ended March 31, 2019 (in thousands, except exercise price): Issued With / For Exercise Warrants 2019 Warrants Issued Warrants Outstanding March 31, 2019 Non-Derivative Warrants: Financing $ 10.00 243 — 243 Financing 15.00 276 — 276 2015 Offering 5.00 3,450 — 3,450 2017 Debt 0.92 443 — 443 2019 Offering 0.2475 — 933 933 2019 Offering 0.253 — 1,065 1,065 Total non-derivative warrants 3.86 B 4,412 1,998 6,410 Derivative Warrants: 2016 Offerings 2.25 A 1,968 — 1,968 2017 Offering 2.35 A 3,500 — 3,500 2017 Offering 2.50 A 175 — 175 Total derivative warrants 2.32 B 5,643 — 5,643 Total $ 3.14 B 10,055 1,998 12,053 A These warrants are subject to fair value accounting and contain a contingent net cash settlement feature. See Note 10. B Weighted-average exercise prices are as of March 31, 2019 .

Fair Value of Warrants

Fair Value of Warrants	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value of Warrants	Fair Value of Warrants The following table summarizes the derivative warrant activity subject to fair value accounting for the three months ended March 31, 2019 (in thousands): Issued with/for Fair value of warrants Change in fair Fair value of warrants 2016 Offerings $ 225 $ 30 $ 255 2017 Offering 23 (23 ) — $ 248 $ 7 $ 255 The derivative warrants issued as part of the 2016 Offerings are valued using a probability-weighted Binomial model, while the derivative warrants issued in conjunction with the 2017 Offering are valued using a Black-Scholes model. The following tables summarize the assumptions used in computing the fair value of derivative warrants subject to fair value accounting at March 31, 2019 and December 31, 2018 . 2016 Offerings As of March 31, 2019 As of December 31, 2018 Exercise price $ 2.25 $ 2.25 Expected life (years) 2.83 3.08 Expected volatility 108.55 % 100.51 % Risk-free interest rate 2.21 % 2.46 % Expected dividend yield — % — % 2017 Offering As of March 31, 2019 As of December 31, 2018 Exercise price $ 2.36 $ 2.36 Expected life (years) 0.19 0.44 Expected volatility 62.86 % 172.5 % Risk-free interest rate 2.44 % 2.56 % Expected dividend yield — % — %

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The Fair Value Measurements and Disclosures Topic of the FASB ASC requires the use of valuation techniques that are consistent with the market approach, the income approach and/or the cost approach. Inputs to valuation techniques refer to the assumptions that market participants would use in pricing the asset or liability. Inputs may be observable, meaning those that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from independent sources, or unobservable, meaning those that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. In that regard, the Topic establishes a fair value hierarchy for valuation inputs that give the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows: Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets that we have the ability to access as of the measurement date. Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. Level 3: Significant unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing an asset or liability. The following table summarizes the financial liabilities measured at fair value on a recurring basis segregated by the level of valuation inputs within the fair value hierarchy utilized to measure fair value (in thousands): March 31, 2019 Total Quoted Prices in Significant Other Significant Warrant liability $ 255 $ — $ — $ 255 Note payable 20 — — 20 Other derivatives 55 — — 55 $ 330 $ — $ — $ 330 December 31, 2018 Total Quoted Prices in Significant Other Significant Warrant liability $ 248 $ — $ — $ 248 Note payable 20 — — 20 Other derivatives 86 $ — $ — 86 $ 354 $ — $ — $ 354 At March 31, 2019 and December 31, 2018 , the Company had a liability payable to VenturEast from a prior acquisition. The ultimate payment to VenturEast will be the fair value of 84,278 shares of our common stock at the time of payment. During the three months ended March 31, 2018 , we recorded a gain of approximately $17,000 due to the change in value of the note. No adjustment was required during the three months ended March 31, 2019 , as the closing price of our common stock on March 31, 2019 was the same as it was on December 31, 2018. At March 31, 2019 , the warrant liability consists of stock warrants issued as part of the 2016 Offerings and 2017 Offering that contain contingent net settlement features. In accordance with derivative accounting for warrants, we calculated the fair value of warrants and the assumptions used are described in Note 10, “Fair Value of Warrants.” During the three months ended March 31, 2019 , we recognized a loss of approximately $7,000 on the derivative warrants. During the three months ended March 31, 2018 , we recorded a gain of approximately $692,000 on the derivative warrants primarily due to changes in our stock price. Realized and unrealized gains and losses related to the change in fair value of the VenturEast note, warrant liability and other derivatives are included in other income (expense) on the Consolidated Statements of Operations and Other Comprehensive Loss. The following table summarizes the activity of the note payable to VenturEast and of our derivative warrants and other derivatives, which were measured at fair value using Level 3 inputs (in thousands): Note Payable Warrant Other to VenturEast Liability Derivatives Fair value at December 31, 2018 $ 20 $ 248 $ 86 Change in fair value — 7 (31 ) Fair value at March 31, 2019 $ 20 $ 255 $ 55

Joint Venture Agreement

Joint Venture Agreement	3 Months Ended
	Mar. 31, 2019
Equity Method Investments and Joint Ventures [Abstract]
Joint Venture Agreement	Joint Venture Agreement In November 2011 , we entered into an affiliation agreement with the Mayo Foundation for Medical Education and Research (“Mayo”), subsequently amended. Under the agreement, we formed a joint venture with Mayo in May 2013 to focus on developing oncology diagnostic services and tests utilizing next generation sequencing. The joint venture is a limited liability company, with each party initially holding fifty percent of the issued and outstanding membership interests of the new entity (the “JV”). The agreement requires aggregate capital contributions by us of up to $6.0 million , of which $2.0 million has been paid to date. The timing of the remaining installments is subject to the JV's achievement of certain operational milestones agreed upon by the board of governors of the JV. In exchange for its membership interest, Mayo’s capital contribution takes the form of cash, staff, services, hardware and software resources, laboratory space and instrumentation, the fair market value of which will be approximately equal to $6.0 million . Mayo’s continued contribution will also be conditioned upon the JV’s achievement of certain milestones. We are in the process of winding down the JV. During the three months ended March 31, 2019 , there was no activity in the JV. Our share of the JV’s net loss was approximately $2,000 for the three months ended March 31, 2018 , and is included in research and development expense on the Consolidated Statements of Operations and Other Comprehensive Loss. We have a net receivable due from the JV of approximately $10,000 at March 31, 2019 , which is included in other assets in the Consolidated Balance Sheets. The joint venture is considered a variable interest entity under ASC 810-10, but we are not the primary beneficiary as we do not have the power to direct the activities of the JV that most significantly impact its performance. Our evaluation of ability to impact performance is based on our equal board membership and voting rights and day-to-day management functions which are performed by the Mayo personnel.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions We had a consulting agreement with Equity Dynamics, Inc. (“EDI”), an entity controlled by the Chairman of our Board of Directors, John Pappajohn, effective April 1, 2014 through August 31, 2018, pursuant to which EDI received a monthly fee of $10,000 . Total expenses for the three months ended March 31, 2018 were $30,000 . As of March 31, 2019 , we owed EDI $70,000 . As described in Note 1, the Company closed two public offerings in January 2019, in which various executives and directors purchased shares at the public offering price. On January 14, 2019, John Pappajohn, John Roberts, our President and Chief Executive Officer, and Geoffrey Harris, a Director, purchased 1,000,000 shares, 100,000 shares and 100,000 shares, respectively, at the public offering price of $0.225 per share. On January 31, 2019, John Pappajohn, John Roberts, Edmund Cannon, a Director, and M. Glenn Miles, our Chief Financial Officer, purchased 1,000,000 shares, 185,436 shares, 43,479 shares and 150,000 shares, respectively, at the public offering price of $0.23 per share.

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies On April 5, 2018 and April 12, 2018, purported stockholders of the Company filed nearly identical putative class action lawsuits in the U.S. District Court for the District of New Jersey, against the Company, Panna L. Sharma, John A. Roberts, and Igor Gitelman, captioned Ben Phetteplace v. Cancer Genetics, Inc. et al ., No. 2:18-cv-05612 and Ruo Fen Zhang v. Cancer Genetics, Inc. et al. , No. 2:18-06353, respectively. The complaints alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 based on allegedly false and misleading statements and omissions regarding our business, operational, and financial results. The lawsuits sought, among other things, unspecified compensatory damages in connection with purchases of our stock between March 23, 2017 and April 2, 2018, as well as interest, attorneys’ fees, and costs. On August 28, 2018, the Court consolidated the two actions in one action captioned In re Cancer Genetics, Inc. Securities Litigation (the “Securities Litigation”) and appointed shareholder Randy Clark as the lead plaintiff. On October 30, 2018, the lead plaintiff filed an amended complaint, adding Edward Sitar as a defendant and seeking, among other things, compensatory damages in connection with purchases of CGI stock between March 10, 2016 and April 2, 2018. On December 31, 2018, Defendants filed a motion to dismiss the amended complaint for failure to state a claim. The Company is unable to predict the ultimate outcome of the Securities Litigation and therefore cannot estimate possible losses or ranges of losses, if any. In addition, on June 1, 2018, September 20, 2018, and September 25, 2018, purported stockholders of the Company filed nearly identical derivative lawsuits on behalf of the Company in the U.S. District Court for the District of New Jersey against the Company (as a nominal defendant) and current and former members of the Company’s Board of Directors and current and former officers of the Company. The three cases are captioned: Bell v. Sharma et al. , No. 2:18-cv-10009-CCC-MF, McNeece v. Pappajohn et al. , No. 2:18-cv-14093, and Workman v. Pappajohn, et al. , No. 2:18-cv-14259 (the “Derivative Litigation”). The complaints allege claims for breach of fiduciary duty, violations of Section 14(a) of the Securities Exchange Act of 1934 (premised upon alleged omissions in the Company’s 2017 proxy statement), and unjust enrichment, and allege that the individual defendants failed to implement and maintain adequate controls, which resulted in ineffective disclosure controls and procedures, and conspired to conceal this alleged failure. The lawsuits seek, among other things, damages and/or restitution to the Company, appropriate equitable relief to remedy the alleged breaches of fiduciary duty, and attorneys’ fees and costs. On November 9, 2018, the Court in the Bell v. Sharma action entered a stipulation filed by the parties staying the Bell action until the Securities Litigation is dismissed, with prejudice, and all appeals have been exhausted; or the defendants’ motion to dismiss in the Securities Litigation is denied in whole or in part; or either of the parties in the Bell action gives 30 days’ notice that they no longer consent to the stay. On December 10, 2018, the parties in the McNeece action filed a stipulation that is substantially identical to the Bell stipulation. On February 1, 2019, the Court in the Workman action granted a stipulation that is substantially identical to the Bell stipulation. The Company is unable to predict the ultimate outcome of the Derivative Litigation and therefore cannot estimate possible losses or ranges of losses, if any.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Sale of NOL’s On April 4, 2019, we sold $11,638,516 of gross State of New Jersey NOL’s relating to the 2017 tax year as well as $71,968 of state research and development tax credits. The sale resulted in the net receipt by the Company of approximately $512,000 . This figure includes all costs and expenses associated with the sale of these state tax attributes as deducted from the gross sales price of approximately $521,000 . Second Standstill On May 3, 2019, we entered into the Second Standstill with Iliad. The Second Standstill provides that Iliad will not seek to redeem any portion of the Convertible Note until May 31, 2019. In consideration for the Second Standstill, we agreed to adjust the conversion price on the first $1,250,000 of our debt to Iliad from $0.80 to $0.2273 . The remaining balance will still be convertible at $0.80 per share. On May 6, 2019 and May 8, 2019, Iliad converted an aggregate of $350,000 of the Convertible Note balance into 1,539,815 shares of our common stock at $0.2273 per share. Nasdaq Notifications Our common stock is listed on the Nasdaq Capital Market. In order to maintain that listing, we must satisfy minimum financial and other requirements including, without limitation, a requirement that our closing bid price be at least $1.00 per share and that we hold an annual meeting of stockholders within twelve months of the end of our fiscal year. In addition, on January 29, 2019, the Company received written notice from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it was required to seek stockholder approval of the execution of the NDX Credit Agreement, under which the Company was advanced $1,500,000 , the outstanding balance of which, including interest, is convertible, at the option of NDX, into shares of common stock at a conversion price of $0.606 per share, due to the potential for the Company, upon a conversion of such outstanding balance, with interest, to be required to issue common stock at a discount to the market price of the common stock on the day of execution of such agreement in excess of 20% of the pre-transaction outstanding shares of common stock, pursuant to Nasdaq Listing Rule 5635(d) (the “Approval Requirement”). Nasdaq’s notice had no immediate effect on the listing of the common stock on the Nasdaq Capital Market. Under Nasdaq Listing Rule 5810(c)(2)(C), the Company had 45 calendar days from January 29, 2019 to submit to Nasdaq a plan to regain compliance with the Approval Requirement, which the Company submitted on March 15, 2019, and which was approved on May 15, 2019, subject to the Company’s shareholders approving the potential issuances to Novellus at the annual meeting of shareholders currently scheduled for May 31, 2019, or the Company otherwise curing the deficiency on or before May 31, 2019. There can be no assurance that the shareholders will approve such issuances. On January 3, 2019, we received written notice from the Listing Qualifications Staff Nasdaq notifying us that we no longer comply with Nasdaq Listing Rule 5620(a) due to our failure to hold an annual meeting of stockholders within twelve months of the end of our fiscal year ended December 31, 2017 (the “Annual Meeting Requirement”). We had 45 calendar days from January 3, 2019, or until February 19, 2019, to submit to Nasdaq a plan to regain compliance with the Annual Meeting Requirement, which we submitted on February 19, 2019. On May 15, 2019, Nasdaq accepted our plan subject to our holding our annual meeting on May 31, 2019. On November 13, 2018, we received a written notice from Nasdaq indicating that we were not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. We had 180 calendar days in which to regain compliance, or until May 13, 2019, which we did not do. On May 15, 2019, Nasdaq granted us an additional 180 days within which to regain compliance.

Organization, Description of _2

Organization, Description of Business, Basis of Presentation, 2019 Offerings, Forbearance Agreements, Standstill Agreements, Recently Adopted Accounting Standard, and Recent Accounting Pronouncements (Policies)	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions for interim reporting as prescribed by the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2018 , filed with the Securities and Exchange Commission on April 16, 2019. The consolidated balance sheet as of December 31, 2018 , included herein was derived from the audited financial statements as of that date, but does not include all disclosures including notes required by GAAP. Interim financial results are not necessarily indicative of the results that may be expected for any future interim period or for the year ending December 31, 2019 .
Derivative Liabilities	Derivative Liabilities The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company’s financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as a liability and the change in fair value is recorded in other income (expense) in the consolidated results of operations. In circumstances where there are multiple embedded instruments that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date. When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption and are classified in interest expense in the consolidated results of operations.
Recent Accounting Pronouncements	Recently Adopted Accounting Standards In February 2016, the Financial Accounting Standards Board (“FASB”) issued guidance codified in Accounting Standards Codification (“ASC”) 842, Leases , which supersedes the guidance in former ASC 840, Leases , to increase transparency and comparability among organizations by requiring recognition of right-of-use assets and lease liabilities on the balance sheet and disclosure of key information about leasing arrangements (with the exception of short-term leases). In July 2018, the FASB issued Accounting Standards Update (“ASU”) 2018-11 to the existing transition guidance that allows entities to recognize a cumulative-effect adjustment to the opening balance of accumulated deficit in the period of adoption. Effective January 1, 2019, we adopted ASC 842 using this new transition guidance. The comparative information has not been restated and continues to be reported under the accounting standard in effect for those periods. We have elected to use the package of practical expedients, which allows us to not (1) reassess whether any expired or existing contracts are considered or contain leases; (2) reassess the lease classification for any expired or existing leases; and (3) reassess the initial direct costs for any existing leases. We did not elect the hindsight practical expedient, which permits entities to use hindsight in determining the lease term and assessing impairment. The most significant impact of adopting ASC 842 is related to the recognition of right-of-use assets and lease liabilities for operating leases. Our accounting for finance leases remains substantially unchanged. The adoption of ASC 842 had no impact on our consolidated statements of operations or total cash flows from operations. The cumulative effect of the changes made to our consolidated January 1, 2019 balance sheet for the adoption of ASC 842 were as follows (in thousands): As of December 31, 2018 Adjustment for Adoption of ASC 842 As of January 1, 2019 ASSETS Operating lease right-of-use assets $ — $ 2,643 $ 2,643 Other current assets 2,148 (78 ) 2,070 $ 2,148 $ 2,565 $ 4,713 LIABILITIES Operating lease liabilities $ — $ 1,080 $ 1,080 Deferred rent payable and other 305 (305 ) — Operating lease liabilities, non-current — 1,790 1,790 $ 305 $ 2,565 $ 2,870 Recent Accounting Pronouncements In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract , which clarifies the accounting for implementation costs in cloud computing arrangements. The update will become effective for interim and annual periods beginning after December 15, 2019 and may be adopted either retrospectively or prospectively. Early adoption is permitted. We plan to adopt this standard prospectively. We are currently evaluating the impact that adoption of this ASU will have on our consolidated financial statements and whether or not to early adopt. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): “ Simplifying the Accounting for Goodwill Impairment ,” which removes the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective for annual periods beginning after December 15, 2019, and interim periods within those annual periods. Early adoption is permitted and applied prospectively. We do not expect ASU 2017-04 to have a material impact on our consolidated financial statements.

Organization, Description of _3

Organization, Description of Business, Basis of Presentation, 2019 Offerings, Forbearance Agreements, Standstill Agreements, Recently Adopted Accounting Standard, and Recent Accounting Pronouncements (Tables)	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Changes for the adoption of ASC 842	The cumulative effect of the changes made to our consolidated January 1, 2019 balance sheet for the adoption of ASC 842 were as follows (in thousands): As of December 31, 2018 Adjustment for Adoption of ASC 842 As of January 1, 2019 ASSETS Operating lease right-of-use assets $ — $ 2,643 $ 2,643 Other current assets 2,148 (78 ) 2,070 $ 2,148 $ 2,565 $ 4,713 LIABILITIES Operating lease liabilities $ — $ 1,080 $ 1,080 Deferred rent payable and other 305 (305 ) — Operating lease liabilities, non-current — 1,790 1,790 $ 305 $ 2,565 $ 2,870

Revenue and Accounts Receivab_2

Revenue and Accounts Receivable (Tables)	3 Months Ended
	Mar. 31, 2019
Revenue from Contract with Customer [Abstract]
Schedule of revenue by service type	Revenue by service type for the three months ended March 31, 2019 and 2018 is comprised of the following (in thousands): Three Months Ended March 31, 2019 2018 Biopharma Services $ 3,964 $ 3,658 Clinical Services 1,353 2,342 Discovery Services 1,522 1,667 $ 6,839 $ 7,667
Schedule of accounts receivable by service type	Accounts receivable by service type at March 31, 2019 and December 31, 2018 consists of the following (in thousands): March 31, December 31, Biopharma Services $ 3,967 $ 3,692 Clinical Services 5,906 6,031 Discovery Services 881 777 Allowance for doubtful accounts (3,462 ) (3,462 ) $ 7,292 $ 7,038
Schedule of clinical services revenue (as a percent of total revenue)	The breakdown of our Clinical Services revenue (as a percent of total revenue) is as follows: Three Months Ended March 31, 2019 2018 Medicare 5% 9% Other third party payors 15% 21% 20% 30%

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Summary of anti-dilutive equivalent units outstanding excluded from earnings per share calculation	The following table summarizes equivalent units outstanding that were excluded from the earnings per share calculation because their effects were anti-dilutive (in thousands): Three Months Ended March 31, 2019 2018 Common stock purchase warrants 12,053 10,055 Stock options 2,290 2,534 Convertible note 3,767 — Advance from NovellusDx, Ltd. 2,690 — Restricted shares of common stock 28 683 20,828 13,272

Leasing Arrangments (Tables)

Leasing Arrangments (Tables)	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Components of lease expense and supplemental information	The components of lease expense were as follows for the three months ended March 31, 2019 (in thousands): Operating lease cost $ 276 Short-term lease cost 24 Variable lease cost 62 Total lease expense $ 362 Other supplemental information related to leases was as follows for the three months ended March 31, 2019 : Weighted average remaining lease term (in years) Operating leases 3.18 Weighted average discount rate Operating leases 7.87 %
Schedule of future estimated minimum lease payments under non-cancelable operating leases	At March 31, 2019 , future estimated minimum lease payments under non-cancelable operating leases were as follows (in thousands): 2019 (remaining 9 months) $ 860 2020 966 2021 598 2022 563 2023 94 Total minimum lease payments 3,081 Less amount representing interest 453 Total $ 2,628

Financing (Tables)

Financing (Tables)	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Schedule of convertible debt	The Convertible Note is the general unsecured obligation of the Company and is subordinated in right of payment to the ABL and PFG Term Note. The following is a summary of the Convertible Note balance at March 31, 2019 (in thousands): Convertible Note, net of discounts of $46 $ 2,781 Less unamortized debt issuance costs 3 Convertible Note, net $ 2,778

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of employee and nonemployee stock option activity	A summary of employee and non-employee stock option activity for the three months ended March 31, 2019 is as follows: Options Outstanding Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Number of Shares (in thousands) Weighted- Average Exercise Price Outstanding January 1, 2019 3,004 $ 5.77 5.70 $ — Granted 95 0.44 Cancelled or expired (809 ) 8.00 Outstanding March 31, 2019 2,290 $ 4.76 7.13 $ — Exercisable March 31, 2019 1,189 $ 7.94 5.42 $ —
Weighted-average assumptions used to estimate fair value of options granted	The following table presents the weighted-average assumptions used to estimate the fair value of options granted to employees during the periods presented: Three Months Ended March 31, 2019 Volatility 90.15 % Risk free interest rate 2.54 % Dividend yield 0.00 % Term (years) 6.32 Weighted-average fair value of options granted during the period $ 0.34
Nonvested restricted stock shares activity	The following table summarizes the activities for our non-vested restricted stock awards for the three months ended March 31, 2019 : Non-vested Restricted Stock Awards Number of Weighted-Average Grant Date Fair Value Non-vested at January 1, 2019 29 $ 3.43 Cancelled (1 ) 6.30 Non-vested at March 31, 2019 28 $ 3.33
Effects of stock-based compensation related to stock option and restricted stock awards	The following table presents the effects of stock-based compensation related to stock option and restricted stock awards to employees and non-employees on our Consolidated Statements of Operations and Other Comprehensive Loss during the periods presented (in thousands): Three Months Ended March 31, 2019 2018 Cost of revenues $ 28 $ 91 Research and development 8 15 General and administrative 116 158 Sales and marketing 6 10 Total stock-based compensation $ 158 $ 274

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Summary of warrant activity	The following table summarizes the warrant activity for the three months ended March 31, 2019 (in thousands, except exercise price): Issued With / For Exercise Warrants 2019 Warrants Issued Warrants Outstanding March 31, 2019 Non-Derivative Warrants: Financing $ 10.00 243 — 243 Financing 15.00 276 — 276 2015 Offering 5.00 3,450 — 3,450 2017 Debt 0.92 443 — 443 2019 Offering 0.2475 — 933 933 2019 Offering 0.253 — 1,065 1,065 Total non-derivative warrants 3.86 B 4,412 1,998 6,410 Derivative Warrants: 2016 Offerings 2.25 A 1,968 — 1,968 2017 Offering 2.35 A 3,500 — 3,500 2017 Offering 2.50 A 175 — 175 Total derivative warrants 2.32 B 5,643 — 5,643 Total $ 3.14 B 10,055 1,998 12,053 A These warrants are subject to fair value accounting and contain a contingent net cash settlement feature. See Note 10. B Weighted-average exercise prices are as of March 31, 2019 .

Fair Value of Warrants (Tables)

Fair Value of Warrants (Tables)	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Schedule of derivative warrant liability	The following table summarizes the derivative warrant activity subject to fair value accounting for the three months ended March 31, 2019 (in thousands): Issued with/for Fair value of warrants Change in fair Fair value of warrants 2016 Offerings $ 225 $ 30 $ 255 2017 Offering 23 (23 ) — $ 248 $ 7 $ 255
Assumptions used in computing fair value of derivative warrants	The following tables summarize the assumptions used in computing the fair value of derivative warrants subject to fair value accounting at March 31, 2019 and December 31, 2018 . 2016 Offerings As of March 31, 2019 As of December 31, 2018 Exercise price $ 2.25 $ 2.25 Expected life (years) 2.83 3.08 Expected volatility 108.55 % 100.51 % Risk-free interest rate 2.21 % 2.46 % Expected dividend yield — % — % 2017 Offering As of March 31, 2019 As of December 31, 2018 Exercise price $ 2.36 $ 2.36 Expected life (years) 0.19 0.44 Expected volatility 62.86 % 172.5 % Risk-free interest rate 2.44 % 2.56 % Expected dividend yield — % — %

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Summary of financial liabilities measured at fair value on a recurring basis	The following table summarizes the financial liabilities measured at fair value on a recurring basis segregated by the level of valuation inputs within the fair value hierarchy utilized to measure fair value (in thousands): March 31, 2019 Total Quoted Prices in Significant Other Significant Warrant liability $ 255 $ — $ — $ 255 Note payable 20 — — 20 Other derivatives 55 — — 55 $ 330 $ — $ — $ 330 December 31, 2018 Total Quoted Prices in Significant Other Significant Warrant liability $ 248 $ — $ — $ 248 Note payable 20 — — 20 Other derivatives 86 $ — $ — 86 $ 354 $ — $ — $ 354
Schedule of fair value notes payable of business acquisition and warrant liability	The following table summarizes the activity of the note payable to VenturEast and of our derivative warrants and other derivatives, which were measured at fair value using Level 3 inputs (in thousands): Note Payable Warrant Other to VenturEast Liability Derivatives Fair value at December 31, 2018 $ 20 $ 248 $ 86 Change in fair value — 7 (31 ) Fair value at March 31, 2019 $ 20 $ 255 $ 55

Organization, Description of _4

Organization, Description of Business, Basis of Presentation, 2019 Offerings, Forbearance Agreements, Standstill Agreements, Recently Adopted Accounting Standard, and Recent Accounting Pronouncements - 2019 Offerings (Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 26, 2019	Jan. 09, 2019	Jan. 31, 2019	Jan. 14, 2019
Class of Stock [Line Items]
Warrants, number of shares of common stock with right to purchase (in shares)		933,334		933,334
Warrants, exercise price (usd per share)		$ 0.2475		$ 0.2475
Warrants, exercise period		5 years
H.C. Wainwright, underwriter
Class of Stock [Line Items]
Warrants, number of shares of common stock with right to purchase (in shares)	1,065,217	13,333,334	1,065,217
Warrants, exercise price (usd per share)	$ 0.253	$ 0.225	$ 0.253
Warrants, exercise period	5 years
Public Offering
Class of Stock [Line Items]
Warrants, number of shares of common stock with right to purchase (in shares)	15,217,392
Warrants, exercise price (usd per share)	$ 0.23
Proceeds received	$ 2,975	$ 2,437
Stock issuance costs	$ 525	$ 563

Organization, Description of _5

Organization, Description of Business, Basis of Presentation, 2019 Offerings, Forbearance Agreements, Standstill Agreements, Recently Adopted Accounting Standard, and Recent Accounting Pronouncements - Additional Information (Details) - USD ($)	Feb. 15, 2019	Jan. 29, 2019	Jan. 16, 2019	Sep. 18, 2018	Mar. 22, 2017	May 20, 2019	Jan. 31, 2019	May 03, 2019	Mar. 31, 2019	Dec. 15, 2018	Jul. 17, 2018
NDX | Credit Agreement
Debt Instrument [Line Items]
Conversion price (in usd per share)		$ 0.606								$ 0.606
Advance from related party		$ 1,500,000		$ 1,500,000
Stated interest rate (percent)				10.75%						21.00%
Prime Rate | Silicon Valley Bank | Line of Credit
Debt Instrument [Line Items]
Basis spread on variable rate (percent)			2.25%		1.50%		2.25%
Secured Debt | PFG
Debt Instrument [Line Items]
Term note, principal balance			$ 6,000,000		$ 6,000,000				$ 6,000,000
Convertible Debt
Debt Instrument [Line Items]
Term note, principal balance											$ 2,625,000
Debt balance if converted	$ 202,000
Conversion price (in usd per share)											$ 0.80
Stated interest rate (percent)											10.00%
Subsequent events
Debt Instrument [Line Items]
Share issued upon conversion of convertible note						1,539,815
Subsequent events | Convertible Debt, Adjusted Conversion Price Portion
Debt Instrument [Line Items]
Term note, principal balance								$ 1,250,000
Conversion price (in usd per share)						$ 0.2273		$ 0.2273

Organization, Description of _6

Organization, Description of Business, Basis of Presentation, 2019 Offerings, Forbearance Agreements, Standstill Agreements, Recently Adopted Accounting Standard, and Recent Accounting Pronouncements - Schedule of Changes for the adoption of ASC 842 (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
ASSETS
Operating lease right-of-use assets	$ 2,422	$ 2,643
Other current assets	2,344	2,070	$ 2,148
Assets effected by accounting change		4,713	2,148
LIABILITIES
Operating lease liabilities	1,086	1,080
Deferred rent payable and other	0		305
Operating lease liabilities, non-current	$ 1,542	1,790
Liabilities effected by accounting change		2,870	$ 305
Adjustment for Adoption of ASC 842
ASSETS
Operating lease right-of-use assets		2,643
Other current assets		(78)
Assets effected by accounting change		2,565
LIABILITIES
Operating lease liabilities		1,080
Deferred rent payable and other		(305)
Operating lease liabilities, non-current		1,790
Liabilities effected by accounting change		$ 2,565

Going Concern - Narrative (Deta

Going Concern - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net cash used in operating activities	$ 4,465	$ 4,472
Unrestricted cash and cash equivalents	697		$ 161
Negative working capital	$ 18,000

Revenue and Accounts Receivab_3

Revenue and Accounts Receivable - Schedule of Revenue by Service Type (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 6,839	$ 7,667
Biopharma Services
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	3,964	3,658
Clinical Services
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	1,353	2,342
Discovery Services
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 1,522	1,667
India Subsidiary | Discovery Services
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue		$ 239

Revenue and Accounts Receivab_4

Revenue and Accounts Receivable - Schedule of Accounts Receivable by Service Type (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for doubtful accounts	$ (3,462)	$ (3,462)
Accounts receivable, net	7,292	7,038
Biopharma Services
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	3,967	3,692
Clinical Services
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	5,906	6,031
Discovery Services
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 881	$ 777

Revenue and Accounts Receivab_5

Revenue and Accounts Receivable - Schedule of Clinical Services Revenue (Details) - Payor - Revenue	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Product Information [Line Items]
Percentage of revenue	20.00%	30.00%
Medicare
Product Information [Line Items]
Percentage of revenue	5.00%	9.00%
Other third party payors
Product Information [Line Items]
Percentage of revenue	15.00%	21.00%

Revenue and Accounts Receivab_6

Revenue and Accounts Receivable - Performance Obligations (Details) $ in Millions	Mar. 31, 2019USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01 | Clinical Services And Discovery Services
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-04-01 | Biopharma Services
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	2 years
Revenue, remaining performance obligation	$ 36.8

Earnings Per Share - Summary of

Earnings Per Share - Summary of Anti-Dilutive Equivalent Units Outstanding Excluded From Calculation of Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation (in shares)	20,828	13,272
Common stock purchase warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation (in shares)	12,053	10,055
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation (in shares)	2,290	2,534
Convertible note
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation (in shares)	3,767	0
Advance from NovellusDx, Ltd.
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation (in shares)	2,690	0
Restricted shares of common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation (in shares)	28	683

Leasing Arrangments - Component

Leasing Arrangments - Components of lease expense and supplemental information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Lease expense
Operating lease cost	$ 276
Short-term lease cost	24
Variable lease cost	62
Total lease expense	$ 362
Operating leases
Weighted average remaining lease term (in years)	3 years 2 months 5 days
Weighted average discount rate	7.87%

Leasing Arrangments - Schedule

Leasing Arrangments - Schedule of future estimated minimum lease payments under non-cancelable operating leases (Details) $ in Thousands	Mar. 31, 2019USD ($)
Leases [Abstract]
2019 (remaining 9 months)	$ 860
2020	966
2021	598
2022	563
2023	94
Total minimum lease payments	3,081
Less amount representing interest	453
Total	$ 2,628

Financing - Additional Informat

Financing - Additional Information (Details)

Jan. 29, 2019USD ($)$ / shares

Jan. 16, 2019USD ($)

Jan. 09, 2019$ / sharesshares

Sep. 18, 2018USD ($)

Jul. 17, 2018USD ($)day$ / shares

Mar. 22, 2017USD ($)

May 20, 2019USD ($)$ / sharesshares

Jan. 31, 2019

May 03, 2019USD ($)$ / shares

Mar. 31, 2019USD ($)

Jan. 14, 2019$ / sharesshares

Dec. 31, 2018USD ($)

Dec. 15, 2018$ / shares

Aug. 31, 2018USD ($)

Debt Instrument [Line Items]

Line of credit

$ 2,414,000

$ 2,621,000

Warrants, exercise period

5 years

Warrants, number of shares of common stock with right to purchase (in shares) | shares

933,334

933,334

Warrants, exercise price (usd per share) | $ / shares

$ 0.2475

$ 0.2475

Term note

6,000,000

$ 6,000,000

Convertible Debt

Debt Instrument [Line Items]

Debt instrument term

18 months

Term note, principal balance

$ 2,625,000

Proceeds from Convertible Note

2,500,000

Original issue discount

100,000

Beneficial conversion feature on Convertible Note

328,000

Less unamortized debt issuance costs

$ 25,000

Stated interest rate (percent)

10.00%

Conversion price (in usd per share) | $ / shares

$ 0.80

Number of trading days' notice | day

5

Maximum monthly redemption

$ 650,000

Minimum stock price per share under debt covenant (in usd per share) | $ / shares

$ 1

Debt repayment premium (percent)

10.00%

Period eligible for prepayment at 10% premium

1 year

Increase to outstanding balance upon default (percent)

15.00%

Fair value of default effect

$ 55,000

Interest rate upon reset due to default (percent)

22.00%

Silicon Valley Bank | Line of Credit

Debt Instrument [Line Items]

Debt instrument term

2 years

Line of credit, maximum borrowing capacity (not to exceed)

$ 6,000,000

$ 3,000,000

Line of credit, maximum borrowing capacity, percent of accounts receivable (percent)

80.00%

Line of credit, facility, maximum borrowing capacity, percentage of net collectable value of third party accounts receivable (percent)

50.00%

Line of credit, facility, maximum borrowing capacity, times the average monthly collection amount of third party receivables over a previous quarter

3

Line of credit facility, unused capacity, commitment fee (percent)

0.25%

Effective interest rate (percent)

7.75%

Line of credit

$ 2,400,000

Silicon Valley Bank | Line of Credit | Prime Rate

Debt Instrument [Line Items]

Basis spread on variable rate (percent)

2.25%

1.50%

2.25%

PFG | Secured Debt

Debt Instrument [Line Items]

Debt instrument term

3 years

Effective interest rate (percent)

11.50%

Term note, principal balance

$ 6,000,000

$ 6,000,000

6,000,000

Lender fee

167,000

NDX | Credit Agreement

Debt Instrument [Line Items]

Stated interest rate (percent)

10.75%

21.00%

Conversion price (in usd per share) | $ / shares

$ 0.606

$ 0.606

Advance from related party

$ 1,500,000

$ 1,500,000

Long-term line of credit

1,500,000

Subsequent events

Debt Instrument [Line Items]

Share issued upon conversion of convertible note | shares

1,539,815

Subsequent events | Convertible Debt, Adjusted Conversion Price Portion

Debt Instrument [Line Items]

Term note, principal balance

$ 1,250,000

Conversion price (in usd per share) | $ / shares

$ 0.2273

$ 0.2273

Convertible promissory note to accredited investor | Convertible Note

Debt Instrument [Line Items]

Original issue discount

51,000

Convertible note

$ 2,778,000

Convertible promissory note to accredited investor | Subsequent events | Convertible Note

Debt Instrument [Line Items]

Convertible note

$ 350,000

Financing - Schedule of Convert

Financing - Schedule of Convertible Debt (Details) - Convertible Note - Convertible promissory note to accredited investor $ in Thousands	Mar. 31, 2019USD ($)
Debt Instrument [Line Items]
Convertible note discount	$ 51
Convertible Note, net of discounts of $46	2,781
Less unamortized debt issuance costs	3
Convertible Note, net	$ 2,778

Capital Stock (Details)

Capital Stock (Details) - USD ($)	Jan. 26, 2019	Jan. 09, 2019	May 20, 2019	May 03, 2019	Mar. 31, 2019	Jan. 31, 2019	Jan. 14, 2019
Class of Warrant or Right [Line Items]
Warrants, number of shares of common stock with right to purchase (in shares)		933,334					933,334
Warrants, exercise price (usd per share)		$ 0.2475					$ 0.2475
H.C. Wainwright, underwriter
Class of Warrant or Right [Line Items]
Warrants, number of shares of common stock with right to purchase (in shares)	1,065,217	13,333,334				1,065,217
Warrants, exercise price (usd per share)	$ 0.253	$ 0.225				$ 0.253
Public Offering
Class of Warrant or Right [Line Items]
Warrants, number of shares of common stock with right to purchase (in shares)	15,217,392
Warrants, exercise price (usd per share)	$ 0.23
Proceeds received	$ 2,975,000	$ 2,437,000
Stock issuance costs	$ 525,000	$ 563,000
Convertible promissory note to accredited investor | Convertible Note
Class of Warrant or Right [Line Items]
Convertible note					$ 2,778,000
Subsequent events
Class of Warrant or Right [Line Items]
Share issued upon conversion of convertible note			1,539,815
Subsequent events | Convertible Debt, Adjusted Conversion Price Portion
Class of Warrant or Right [Line Items]
Conversion price (in usd per share)			$ 0.2273	$ 0.2273
Subsequent events | Convertible promissory note to accredited investor | Convertible Note
Class of Warrant or Right [Line Items]
Convertible note			$ 350,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details)	3 Months Ended
	Mar. 31, 2019USD ($)stock_planshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity incentive plans | stock_plan	2
Options granted maximum exercisable period (up to)	10 years
Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested stock options granted	$ 780,553
Unrecognized compensation cost related to non-vested stock options granted expect to recognize, period (in years)	3 years 2 months 12 days
2011 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future awards (in shares) | shares	730,051
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield (percent)	0.00%
Restricted shares of common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested stock options granted expect to recognize, period (in years)	5 months 10 days
Unrecognized compensation cost	$ 34,285

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Employee and Nonemployee Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Options Outstanding, Number of Shares Outstanding
Outstanding, beginning balance (in shares)	3,004,000
Granted (in shares)	95,000
Canceled or expired (in shares)	(809,000)
Outstanding, ending balance (in shares)	2,290,000	3,004,000
Exercisable (in shares)	1,189,000
Options Outstanding, Weighted-Average Exercise Price
Outstanding, beginning balance (usd per share)	$ 5.77
Granted (usd per share)	0.44
Cancelled or expired (usd per share)	8
Outstanding, ending balance (usd per share)	4.76	$ 5.77
Exercisable (usd per share)	$ 7.94
Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value
Weighted- Average Remaining Contractual Term, Outstanding (in years)	7 years 1 month 18 days	5 years 8 months 13 days
Weighted- Average Remaining Contractual Term, Exercisable (in years)	5 years 5 months 2 days
Aggregate Intrinsic Value, Outstanding	$ 0	$ 0
Aggregate Intrinsic Value, Exercisable	$ 0

Stock-Based Compensation - Weig

Stock-Based Compensation - Weighted-Average Assumptions Used to Estimate Fair Value of Options Granted (Details) - Stock options	3 Months Ended
	Mar. 31, 2019$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility (percent)	90.15%
Risk free interest rate (percent)	2.54%
Dividend yield (percent)	0.00%
Term (years)	6 years 3 months 26 days
Weighted-average fair value of options granted during the period (usd per share)	$ 0.34

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Award Activity (Details) - Restricted shares of common stock	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Number of Shares (in shares):
Non-vested, beginning balance (in shares) | shares	29,000
Cancelled (in shares) | shares	(1,000)
Non-vested, ending balance (in shares) | shares	28,000
Weighted-Average Grant Date Fair Value (in dollars per share):
Non-vested, beginning balance (usd per share) | $ / shares	$ 3.43
Cancelled (usd per share) | $ / shares	6.30
Non-vested, ending balance (usd per share) | $ / shares	$ 3.33

Stock-Based Compensation - Effe

Stock-Based Compensation - Effects of Stock-Based Compensation Related to Stock Option Awards (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	$ 158	$ 274
Cost of revenues
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	28	91
Research and development
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	8	15
General and administrative
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	116	158
Sales and marketing
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	$ 6	$ 10

Warrants - Additional Informati

Warrants - Additional Information (Details) - $ / shares	Jan. 31, 2019	Jan. 26, 2019	Jan. 14, 2019	Jan. 09, 2019
Class of Warrant or Right [Line Items]
Warrants, number of shares of common stock with right to purchase (in shares)			933,334	933,334
Warrants, exercise price (usd per share)			$ 0.2475	$ 0.2475
H.C. Wainwright, underwriter
Class of Warrant or Right [Line Items]
Warrants, number of shares of common stock with right to purchase (in shares)	1,065,217	1,065,217		13,333,334
Warrants, exercise price (usd per share)	$ 0.253	$ 0.253		$ 0.225

Warrants - Summary of Warrant A

Warrants - Summary of Warrant Activity (Details) - $ / shares shares in Thousands	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share)	$ 3.14
Warrants Outstanding (in shares)	12,053	10,055
Warrants Issued (in shares)	1,998
Warrant Issued With | Non-derivative warrants
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share)	$ 3.86
Warrants Outstanding (in shares)	6,410	4,412
Warrants Issued (in shares)	1,998
Warrant Issued For | Derivative warrants
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share)	$ 2.32
Warrants Outstanding (in shares)	5,643	5,643
Warrants Issued (in shares)	0
Financing | Warrant Issued With | Non-derivative warrants
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share)	$ 10
Warrants Outstanding (in shares)	243	243
Warrants Issued (in shares)	0
Financing | Warrant Issued With | Non-derivative warrants
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share)	$ 15
Warrants Outstanding (in shares)	276	276
Warrants Issued (in shares)	0
2017 Debt | Warrant Issued With | Non-derivative warrants
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share)	$ 0.92
Warrants Outstanding (in shares)	443	443
Warrants Issued (in shares)	0
2015 Offering | Warrant Issued With | Non-derivative warrants
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share)	$ 5
Warrants Outstanding (in shares)	3,450	3,450
Warrants Issued (in shares)	0
2019 Offering | Warrant Issued With | Non-derivative warrants
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share)	$ 0.2475
Warrants Outstanding (in shares)	933	0
Warrants Issued (in shares)	933
2019 Offering | Warrant Issued With | Non-derivative warrants
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share)	$ 0.253
Warrants Outstanding (in shares)	1,065	0
Warrants Issued (in shares)	1,065
2016 Offerings | Warrant Issued For | Derivative warrants
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share)	$ 2.25
Warrants Outstanding (in shares)	1,968	1,968
Warrants Issued (in shares)	0
2017 Offering | Warrant Issued For | Derivative warrants
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share)	$ 2.35
Warrants Outstanding (in shares)	3,500	3,500
Warrants Issued (in shares)	0
2017 Offering | Warrant Issued For | Derivative warrants
Class of Warrant or Right [Line Items]
Warrants Exercise Price (usd per share)	$ 2.5
Warrants Outstanding (in shares)	175	175
Warrants Issued (in shares)	0

Fair Value of Warrants - Summar

Fair Value of Warrants - Summary of Derivative Warrant Activity (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Class of Warrants Outstanding [Roll Forward]
Fair value of warrants outstanding as of December 31, 2018	$ 248
Change in fair value of warrants	7
Fair value of warrants outstanding as of March 31, 2019	255
2016 Offerings
Class of Warrants Outstanding [Roll Forward]
Fair value of warrants outstanding as of December 31, 2018	225
Change in fair value of warrants	30
Fair value of warrants outstanding as of March 31, 2019	255
2017 Offering
Class of Warrants Outstanding [Roll Forward]
Fair value of warrants outstanding as of December 31, 2018	23
Change in fair value of warrants	(23)
Fair value of warrants outstanding as of March 31, 2019	$ 0

Fair Value of Warrants - Assump

Fair Value of Warrants - Assumptions Used in Computing Fair Value of Derivative Warrants (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Jan. 14, 2019	Jan. 09, 2019
Class of Warrant or Right [Line Items]
Exercise price (usd per share)			$ 0.2475	$ 0.2475
2016 Offering
Class of Warrant or Right [Line Items]
Exercise price (usd per share)	$ 2.25	$ 2.25
Expected life (years)	2 years 10 months	3 years 29 days
2017 Offering
Class of Warrant or Right [Line Items]
Exercise price (usd per share)	$ 2.36	$ 2.36
Expected life (years)	2 months 10 days	5 months 9 days
Expected volatility | 2016 Offering
Class of Warrant or Right [Line Items]
Measurement input assumption (as a percent)	108.55%	100.51%
Expected volatility | 2017 Offering
Class of Warrant or Right [Line Items]
Measurement input assumption (as a percent)	62.86%	172.50%
Risk-free interest rate | 2016 Offering
Class of Warrant or Right [Line Items]
Measurement input assumption (as a percent)	2.21%	2.46%
Risk-free interest rate | 2017 Offering
Class of Warrant or Right [Line Items]
Measurement input assumption (as a percent)	2.44%	2.56%
Expected dividend yield | 2016 Offering
Class of Warrant or Right [Line Items]
Measurement input assumption (as a percent)	0.00%	0.00%
Expected dividend yield | 2017 Offering
Class of Warrant or Right [Line Items]
Measurement input assumption (as a percent)	0.00%	0.00%

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair value measurements, recurring - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Note payable	$ 20	$ 20
Total liabilities fair value	330	354
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Note payable	0	0
Total liabilities fair value	0	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Note payable	0	0
Total liabilities fair value	0	0
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Note payable	20	20
Total liabilities fair value	330	354
Warrant liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	255	248
Warrant liability | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	0	0
Warrant liability | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	0	0
Warrant liability | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	255	248
Other derivatives
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	55	86
Other derivatives | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	0	0
Other derivatives | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	0	0
Other derivatives | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ 55	$ 86

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain (loss) due to change in value of note payable	$ 0	$ (17)
Gain due to expiration of warrant liability	$ (7)	692
VenturEast | BioServe
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Number of shares associated with notes payable (in shares)	84,278
Gain (loss) due to change in value of note payable		17
2016 Offering | Significant Unobservable Inputs (Level 3) | Fair value measurements, recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain due to expiration of warrant liability	$ (7)
Gain (loss) on derivative warrants due to change in stock-price		$ 692

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Fair Value of Notes Payable (Details) - Fair value measurements, recurring - Significant Unobservable Inputs (Level 3) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Note payable | VenturEast
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value at December 31, 2018	$ 20
Change in fair value	0
Fair value at March 31, 2019	20
Warrant liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value at December 31, 2018	248
Change in fair value	7
Fair value at March 31, 2019	255
Other derivatives
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value at December 31, 2018	86
Change in fair value	(31)
Fair value at March 31, 2019	$ 55

Joint Venture Agreement - Addit

Joint Venture Agreement - Additional Information (Details) - USD ($)	3 Months Ended		71 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	May 31, 2013
Schedule of Equity Method Investments [Line Items]
Joint venture net loss	$ 0	$ 2,000
Research and development
Schedule of Equity Method Investments [Line Items]
Joint venture net loss	0	$ 2,000
Equity Method Investee
Schedule of Equity Method Investments [Line Items]
Due from related parties, current	$ 10,000		$ 10,000
Joint Venture Agreement
Schedule of Equity Method Investments [Line Items]
Percentage of outstanding membership interests in joint venture (percent)				50.00%
Investment in joint venture			$ 2,000,000
Fair value of capital contribution in joint venture				$ 6,000,000
Maximum | Joint Venture Agreement
Schedule of Equity Method Investments [Line Items]
Required payments to acquire interest in joint venture				$ 6,000,000

Related Party Transactions (Det

Related Party Transactions (Details)	Jan. 31, 2019$ / sharesshares	Jan. 14, 2019$ / sharesshares	Jan. 31, 2019public_offering$ / shares	Mar. 31, 2018USD ($)	Aug. 31, 2018USD ($)	Mar. 31, 2019USD ($)
Related Party Transaction [Line Items]
Number of public offerings | public_offering			2
Equity Dynamics, Inc.
Related Party Transaction [Line Items]
Agreement with related party, fee | $					$ 10,000
Agreement with related party, consulting fee | $				$ 30,000
Due to related party | $						$ 70,000
Private Placement | John Pappajohn
Related Party Transaction [Line Items]
Shares issues (in shares) | shares	1,000,000	1,000,000
Shares issued, price per share (usd per share) | $ / shares	$ 0.23	$ 0.225	$ 0.23
Private Placement | John Roberts
Related Party Transaction [Line Items]
Shares issues (in shares) | shares	185,436	100,000
Shares issued, price per share (usd per share) | $ / shares	$ 0.23	$ 0.225	0.23
Private Placement | Geoffrey Harris
Related Party Transaction [Line Items]
Shares issues (in shares) | shares		100,000
Shares issued, price per share (usd per share) | $ / shares		$ 0.225
Private Placement | Edmund Cannon
Related Party Transaction [Line Items]
Shares issues (in shares) | shares	43,479
Shares issued, price per share (usd per share) | $ / shares	$ 0.23		0.23
Private Placement | M. Glenn Miles
Related Party Transaction [Line Items]
Shares issues (in shares) | shares	150,000
Shares issued, price per share (usd per share) | $ / shares	$ 0.23		$ 0.23

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	May 15, 2019	Apr. 04, 2019	Jan. 29, 2019	Nov. 13, 2018	Sep. 18, 2018	May 20, 2019	Mar. 31, 2019	May 03, 2019	Dec. 15, 2018	Jul. 17, 2018
Subsequent Event [Line Items]
Minimum closing bid price (in usd per share)							$ 1
Days to regain compliance				180 days
Subsequent events
Subsequent Event [Line Items]
Proceeds from sale of net operating losses		$ 512,000
Gross sales price		521,000
Share issued upon conversion of convertible note						1,539,815
Additional days to regain compliance	180 days
Convertible Debt, Adjusted Conversion Price Portion | Subsequent events
Subsequent Event [Line Items]
Term note, principal balance								$ 1,250,000
Conversion price (in usd per share)						$ 0.2273		$ 0.2273
Convertible Debt
Subsequent Event [Line Items]
Term note, principal balance										$ 2,625,000
Conversion price (in usd per share)										$ 0.80
State and local jurisdiction | New Jersey Division of Taxation | Subsequent events
Subsequent Event [Line Items]
Net operating losses sold		11,638,516
Research and development tax credits | State and local jurisdiction | Subsequent events
Subsequent Event [Line Items]
Research and development tax credits sold		$ 71,968
Convertible promissory note to accredited investor | Convertible Note
Subsequent Event [Line Items]
Convertible note							$ 2,778,000
Convertible promissory note to accredited investor | Convertible Note | Subsequent events
Subsequent Event [Line Items]
Convertible note						$ 350,000
NDX | Credit Agreement
Subsequent Event [Line Items]
Conversion price (in usd per share)			$ 0.606						$ 0.606
Advance from related party			$ 1,500,000		$ 1,500,000
Minimum percent of pre-transaction outstanding shares			20.00%

Uncategorized Items - cgix-2019

Label	Element	Value
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (2,509,000)
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (2,509,000)